Thomas J. Schuetz
CEO & Vice ChairmanDr. Thomas J. Schuetz, also known as Tom, M.D., Ph.D. was co-founded of Compass Therapeutics, Inc in 2014 and he serves as its CEO since May 28, 2024. He also served as President since May 28, 2024 until 2024. He serves as Director of Compass Therapeutics, Inc since 2015 and serves as its Vice Chairman of the Board since January 9, 2024. He served as President of Research & Development until May 28, 2024 and served as its President. Dr. Schuetz is a Co-Founder of Audentes Therapeutics, Inc. He served as the Chief Medical Officer of Therion Biologics Corporation since 2003 and also served as its Senior Vice President. Dr. Schuetz is a senior executive with experience in the biotechnology industry. Dr. Schuetz was a Venture Partner at OrbiMed Advisors LLC, where he worked from November 2007 to May 2012. He served as the Chief Medical Officer of Gelesis, Inc. He served as the Vice President of Clinical Affairs at Transkaryotic Therapies, Inc. (now Shire Pharmaceuticals, Inc.), where he supervised all aspects of clinical development from Phase I through IV. He developed the clinical research program which led to European Union approval of Replagal™. Dr. Schuetz also supervised the Hemophilia A gene therapy clinical development program. Prior to TKT, he served as a Chief Medical Resident at Massachusetts General Hospital. He was an Oncology Fellow at the Dana Farber Cancer Institute in Boston. Dr. Schuetz also serves on the board of directors of Glypharma, Inc. He was a Director of Vifor Pharma, Inc. (formerly known as Relypsa, Inc.). since August 2010. He was a Director of Arteaus Therapeutics and Enobia Pharma. He served as a Director at Alexion Montréal Corp. He served as an Independent Director of Audentes Therapeutics, Inc. from July 2013 to January 15, 2020. He serves as a Member of Scientific Advisory Board and Member of the Advisory Board at Mediphase Venture Partners. He is also associated with Shire Human Genetic Therapies Inc. Dr. Schuetz was a consultant in the biotechnology industry from May 2012 to June 2014, including a consultant for Audentes from July 2012 to June 2013. He holds a Board certification in Internal Medicine and Medical Oncology. Dr. Schuetz received his M.D. from Harvard Medical School, Ph.D. in genetics from Harvard University and B.S. in Chemistry summa cum laude from Xavier University.
公司职务
- 公司名称Compass Therapeutics, Inc.股票代码CMPX职务CEO & Vice Chairman共事同僚
- CLCarl Lee GordonIndependent Chairman
- BSBarry ShinChief Financial Officer
- JEJonathan E. AndermanSenior VP, General Counsel & Corporate Secretary
- NLNeil L. LernerSenior VP & Chief Accounting Officer
- BGBing GongChief Scientific Officer
- PJPhilip J. FerneauIndependent Director
- RSRichard S. LindahlIndependent Director
- FSF. Stephen HodiMember of Clinical Advisory Board
